112208-01-2
Pam3Cys-Ser-(Lys)4 TFA
CAS: 112208-01-2
Molecular Formula: C83H157F3N10O15S
112208-01-2 - Names and Identifiers
| Name | Pam3Cys-Ser-(Lys)4 TFA |
| Synonyms | Pam3CSK4 TFA Pam3Cys-Ser-(Lys)4 TFA Pam3CSK4 TFA (112208-00-1 free base) |
| CAS | 112208-01-2 |
112208-01-2 - Physico-chemical Properties
| Molecular Formula | C83H157F3N10O15S |
| Molar Mass | 1624.28 |
| In vitro study | Pam3CSK4 is a TLR1/2 heterodimer recognises triacylated lipopeptides. Pam3CSK4 (1 μg/mL) enhances the antibacterial functions of granulocyte macrophage-colony stimulating factor (GM-CSF) induced neutrophils to Methicillin-resistant Staphylococcus aureus (MRSA). |
| In vivo study | Pam3CSK4 (5 mg/kg; i.p.; once a day for 9 days) alters brain, spleen and liver weights in neonatal mice. Animal Model: Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2 tm1Kir /J (TLR2 -deficient) mice Dosage: 5 mg/kg Administration: Intraperitoneally (i.p.); once a day for 9 days Result: After repeated administration from postnatal day (PND3) to PND11, brain weight was decreased compared with endotoxin-free saline-treated animals at PND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at PND12. |
112208-01-2 - Reference Information
| biological activity | Pam3CSK4 TFA is a Toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2. |
| in vitro study | Pam3CSK4 is a TLR1/2 heterodimer recognizes triacylated lipopeptides. Pam3CSK4 (1 μg/mL) enhances the antibacterial functions of granulocyte macrophage-colony stimulating factor (GM-CSF) induced neutrophils to Methicillin-resistant Staphylococcus aureus (MRSA). |
| in vivo study | Pam3CSK4 (5 mg/kg; I. p.; Once a day for 9 days) alters brain, spleen and liver weights in neonatal mice. Animal Model: Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2 tm1Kir /J (TLR2 -deficient) MICE Dosage: 5 mg/kg Administration: intraperitoneally (I. p.); Once a day for 9 days result: after repeated administration from postnatal day (pND3) to pND11, brain weight was decreased compared with endotoxin-free saline-treated animals at pND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at pND12. |
| Animal Model: | Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2 tm1Kir /J (TLR2 -deficient) mice |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneally (I .p.); once a day for 9 days |
| Result: | After repeated administration from postnatal day (PND3) to PND11, brain weight was decreased compared with endotoxin-free saline-treated animals at PND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at PND12. |
Last Update：2024-04-09 21:11:58
